Oncolytics Biotech Inc. - Shareholder/Analyst Call Transcript
Good morning. My name is Sherri, and I'll be your conference operator today. At this time, I would like to welcome everybody to Oncolytics Biotech conference call to discuss the codevelopment agreement with Pfizer and Merck KGaA. (Operator Instructions)
I will now turn the conference call over to your host, Michael Moore, Vice President, Investor Relations and Corporate Communications. Mr. Moore, please go ahead.
Thank you, Sherri. Good morning, ladies and gentlemen, and thank you for joining us on our call today to discuss this very important codevelopment agreement. With me on the call this morning from Oncolytics are Dr. Matt Coffey, President and Chief Executive Officer; Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development; and Kirk Look, Chief Financial Officer.
On today's call, Dr. Coffey will discuss the codevelopment agreement announced this morning between Oncolytics and pharma partners Pfizer and Merck KGaA
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |